PBYI
$7.01
Puma Biotechnology
($.34)
(4.63%)
PBYI
Earnings Whisper ®
N/A
1st Quarter March 2020
Consensus:  ($0.76)
Revenue:  $44.85 Mil
Thursday
May 21
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when PBYI reports earnings?
Beat
Meet
Miss

Where is PBYI's stock price going from here?
Up
Flat
Down
Stock chart of PBYI
Analysts
Summary of analysts' recommendations for PBYI
Score
Grade
Pivots
Resistance
$8.08
$7.78
$7.40

$7.10

Support
$6.72
$6.42
$6.04
Tweet
Growth
Description
Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer and PB272 (neratinib intravenous) for the treatment of patients with advanced cancer. Puma Biotechnology, Inc. is headquartered in Los Angeles, California.
Peers
BioMarin PharmaceuticalRegeneron PharmaceuticalsVertex PharmaceuticalsJohnson & JohnsonInterCeptZoetisBristol-Myers SquibbMylanUltragenyx PharmaceuticalAlkermes